{"id":390726,"date":"2018-03-20T00:00:00","date_gmt":"2018-03-20T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoop0001-2018-biopharma-dry-and-wet-age-related-macular-degeneration-treatment-algorithms-claims-data-analysis-wet-age\/"},"modified":"2026-04-22T05:25:26","modified_gmt":"2026-04-22T05:25:26","slug":"algoop0001-2018-biopharma-dry-and-wet-age-related-macular-degeneration-treatment-algorithms-claims-data-analysis-wet-age","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoop0001-2018-biopharma-dry-and-wet-age-related-macular-degeneration-treatment-algorithms-claims-data-analysis-wet-age\/","title":{"rendered":"Dry and Wet Age-Related Macular Degeneration | Treatment Algorithms: Claims Data Analysis | Wet Age-Related Macular Degeneration | US | 2018"},"content":{"rendered":"<p>The wet age-related macular degeneration (<abbr title=\"age-related macular degeneration\">AMD<\/abbr>) therapy market in the United States is unique given the dominance of Genentech\u2019s Avastin, an oncology drug that is used off-label to treat wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr>, despite the availability of two highly efficacious approved therapies\u2014Genentech\u2019s Lucentis and Regeneron\u2019s Eylea. These current therapies, which target vascular endothelial growth factor (<abbr title=\"vascular endothelial growth factor\">VEGF<\/abbr>) and have been shown to maintain and even improve visual acuity in wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> patients, compete directly for patient share. It is essential to understand the use of these agents in the nuanced wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> treatment algorithm ahead of anticipated launches of emerging products.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What patient share do key therapies and brands garner by line of therapy in newly diagnosed wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> patients?<\/li>\n<li>How do wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> patients progress through lines of therapy, and how long do they remain on treatment before progressing?<\/li>\n<li>What proportion of wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?<\/li>\n<li>Are most recently treated wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> patients with each key brand coming through new (adds\/switches) or continuing business?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients with wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr>? How do physicians\u2019 decisions regarding brand dosing frequency impact traditional measures of persistence and compliance?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION <\/strong><\/p>\n<p><em>Treatment Algorithms: Claims Data Analysis<\/em> provides detailed analysis of brand use across different lines of therapy using real-world patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand share.<\/p>\n<p><strong>Markets covered:<\/strong> United States<\/p>\n<p><strong>Real-world data:<\/strong> Longitudinal patient-level claims data analysis<\/p>\n<p><strong>Key companies: <\/strong> Genentech, Regeneron, Valeant Pharmaceuticals<\/p>\n<p><strong>Key drugs:<\/strong> Lucentis, Avastin, Eylea, Visudyne, Macugen<\/p>\n<p><strong>Key analysis provided:<\/strong><\/p>\n<ul>\n<li>Brand use across longitudinal patient sample.<\/li>\n<li>Newly diagnosed patient analysis.<\/li>\n<li>Treatment initiation and progression.<\/li>\n<li>Line of therapy analysis.<\/li>\n<li>Combination therapy analysis.<\/li>\n<li>Source of business for recently treated patients.<\/li>\n<li>Persistency and compliance analysis.<\/li>\n<li>Product-level patient flowcharts.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390726","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-age-related-macular-degeneration","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390726","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390726\/revisions"}],"predecessor-version":[{"id":393850,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390726\/revisions\/393850"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390726"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}